Loading
BioVersys AG Stock: price and insider trades · Switzerland
No insider purchase over the last 90 days. The latest was filed 14 May 2026.
BioVersys AG: what insiders have been doing
This page follows insider dealings at BioVersys AG as filed with SIX SER, a company from the Health Care sector based in Basel, Switzerland. The last twelve months, up to 18 October 2026, brought 6 filings signed by 2 insiders.
Only purchases show up on the open market, 4 purchases in all worth €5,617, filed by 2 insiders. Unlike grants, an open-market purchase is paid for by the insider, at the market price. One trade stands out by size: a purchase of €2,011, disclosed on 14 May 2026, or 0.0013% of market capitalisation. The buyers include 2 senior executives.
Compared with its exchange (178 companies, median 9 filings), a count of 6 filings is below the norm. The full history, which starts in 2025, counts 4 purchases against no sales.
In all, 1 purchase was made within 30 days of a purchase by another insider of the company. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 14 May 2026, 156 days ago. Most trades are made public on the day they happen. Until a filing is published, the market cannot know about the trade.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SIX SER. Past trades are no guide to future returns.
Key facts
Headquarters: Basel, Switzerland
Source: Wikidata (CC0).
Insider Decl.
6
Thresholds
n/a
Buy Volume
€5,617
4 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleAnonymous (Non-executive member of the board of directors)3 buys
Anonymous (a non-executive member of the board of directors)1 buy
Since the insiders bought
- Anonymous (a non-executive member of the board of directors)-1.5%Entry CHF 26.30 · Close 14 Oct 2026 CHF 25.90
- Anonymous (Non-executive member of the board of directors)-3.7%Entry CHF 26.90 · Close 14 Oct 2026 CHF 25.90
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
CHF 24.80
Analyst consensus
5 analysts1.00/5
CHF 40.00Target CHF 58.26(+135%)CHF 71.30
Income statement
RevenueCHF 800k
Gross profit-CHF 3.1M-387% margin
EBITDA-CHF 20.4M-2555% margin
Net income-CHF 21.8M-2728.8% margin
Valuation
PER (forward)-4.3x
P/Book2.4x
Balance sheet & cash
Market capCHF 145M
Total debtCHF 21.7M
Free Cash Flow-CHF 22.2M
Debt / Equity36%
Profitability & ownership
ROE-61.9%
ROA-19.9%
% insiders33.7%
% institutions12.8%
Last declaration on 14 May 2026
Declarations6 total
1,839 shares@ CHF 1.000.0013% mcap3.6% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q5E00016
Canonical exit: 12 Aug 2026 (T+90)
1,839 shares@ CHF 1.000.0013% mcap3.5% of flowISIN CH0210362643SIX:T1Q5E00016
Canonical exit: 12 Aug 2026 (T+90)
1,757 shares@ CHF 28.460.031% mcap96.4% of flowSIX:https://www.ser-ag.com/en/resources/notifications-market-participants/management-transactions.html#/transaction-details/T1Q5C00085
1,757 shares@ CHF 28.45760.035% mcap93.8% of flowSIX:T1Q5C00085
469 shares@ CHF 1.000.0003% mcap0.9% of flowISIN CH0210362643SIX:T1Q3Q00080
Canonical exit: 24 Jun 2026 (T+90)
1,000 shares@ CHF 1.001.9% of flowISIN CH0210362643SIX:T1PBH000D0
Canonical exit: 15 Feb 2026 (T+90)
6 of 6 declarations
About BioVersys AG
BioVersys AG is a biopharmaceutical company focused on developing treatments for resistant bacterial infections. It is listed on the Swiss stock exchange XSWX.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
